Novorapid and Angioedema - a phase IV clinical study of FDA data

Summary:

Angioedema is reported as a side effect among people who take Novorapid (insulin aspart recombinant), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lantus, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Angioedema when taking Novorapid. It is created by eHealthMe based on reports of 24,590 people who have side effects when taking Novorapid from the FDA, and is updated regularly.

What is Novorapid?

Novorapid has active ingredients of insulin aspart recombinant. It is often used in type 1 diabetes. eHealthMe is studying from 24,730 Novorapid users. Check the latest studies of Novorapid.

What is Angioedema?

Angioedema (rapid swelling of the dermis) is found to be associated with 1,199 drugs and 2,100 conditions by eHealthMe. Check the latest studies of Angioedema.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

24,590 people reported to have side effects when taking Novorapid.
Among them, 82 people (0.33%) have Angioedema.

Among these 82 people:

How long have people been on Novorapid when they have Angioedema? *

What is the gender of people who have Angioedema when taking Novorapid? *

female: 62.5 %
male: 37.5 %

What is the age of people who have Angioedema when taking Novorapid? *

What are other drugs people take besides Novorapid? *

What are other side effects people have besides Angioedema? *

Rashes (redness): 23 people, 28.05%
Nausea (feeling of having an urge to vomit): 15 people, 18.29%
Urticaria (rash of round, red welts on the skin that itch intensely): 12 people, 14.63%
Swelling Face: 10 people, 12.20%
Chest Pain: 9 people, 10.98%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 7 people, 8.54%
Abdominal Discomfort: 7 people, 8.54%
Hyperglycemia (high blood sugar): 7 people, 8.54%
Atelectasis (partial or complete collapse of the lung): 7 people, 8.54%
Fever: 6 people, 7.32%

What are the existing conditions these people have? *

Type 2 Diabetes: 18 people, 21.95%
High Blood Pressure: 13 people, 15.85%
High Blood Cholesterol: 6 people, 7.32%
Asthma: 6 people, 7.32%
Chronic Thyroiditis (long lasting inflammation of thyroid gland): 6 people, 7.32%
Vitamin B12 Deficiency: 5 people, 6.10%
Urticaria (rash of round, red welts on the skin that itch intensely): 5 people, 6.10%
Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi): 5 people, 6.10%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 5 people, 6.10%
Lung Disorder (lung disease): 5 people, 6.10%

* Approximation only. Some reports may have incomplete information.

Do you take Novorapid and have Angioedema?

- Check whether Angioedema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Novorapid:

Novorapid (24,730 reports)

Angioedema treatments and more:

Angioedema (44,989 reports)

Browse all side effects of Novorapid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Angioedema:

Angioedema (1,199 drugs)

Browse all the conditions that are associated with Angioedema:

Angioedema (2,100 conditions)

Related publications that referenced our studies

Banaga, Y., Mohmmed, K., Mustafa, H., & Barrett, J, "Angioedema 2 months after Administration of Rivaroxaban (Xarelto)", J Clin Case Rep, 2014 Jan .
Banaga, Y., Mohmmed, K., Mustafa, H., & Barrett, J, "Angioedema 2 months after Administration of Rivaroxaban (Xarelto)", J Clin Case Rep, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on insulin aspart recombinant (the active ingredients of Novorapid) and Novorapid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.